The Industry

December 2006
Pharmaceutical Representative;Dec2006, Vol. 36 Issue 12, p10
The article offers global news briefs related to pharmaceutical industry. UCB Group Ltd. has offered €4.4 billion to acquire Schwarz Pharma AG. Roche Pharmaceuticals and InterMune Inc. have agreed to collaborate in the development and commercialization of hepatitis C virus protease inhibitors. NitroMed Inc. is planning to dismantle its current sales force.


Related Articles

  • Roche: strengthening its HCV pipeline.  // PharmaWatch: Monthly Review;Dec2006, Vol. 5 Issue 12, p24 

    The author reflects on the move of pharmaceutical company Roche Pharmaceuticals to collaborate with InterMune Inc. in developing an inhibitor for Hepatitis C virus (HCV). According to the author, the drive will strengthen the status of Roche to the HCV market in the face of strong competition...

  • Intermune up on buyout buzz. Investor's Business Daily // Investors Business Daily;8/14/2014, pA02 

    The article reports on the potential buyers of biotechnology company InterMune including drugmakers Roche, Sanofi, and GlaxoSmithKline.

  • Roche's $8.3B InterMune buy continues its buying spree with 'bolt-on' deal, fueling record M&A activity. Rosenberg, Ronald // CenterWatch Weekly;9/2/2014, Vol. 18 Issue 34, p1 

    The article reports that global pharmaceutical company F. Hoffmann-La Roche Ltd. has continued its targeted buying spree by paying $8.3 billion for idiopathic pulmonary fibrosis (IPF) drug developer InterMune Inc. It mentions that the deal follows a record of six months of mergers and...

  • Roche.  // Formulary;Oct2000 Resource Guide, Vol. 35 Issue 10, p83 

    Features the Roche Holding Ltd., a pharmaceutical manufacturer. Focus of its international research and development efforts; Total shares at the biotechnology company, Genentech Inc.; Pharmaceutical products that have received approval from the United States Food and Drug Administration.

  • Legal costs batter Roche's profits. Beacham, Will // European Chemical News;3/3/2003, Vol. 78 Issue 2042, p9 

    Reports the financial performance of Swiss pharmaceutical company Roche in 2002. Factors that influenced its financial performance; Overview of its financial results; Expectations for 2003.

  • Global Report.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p10 

    The article offers information related to the pharmaceutical industry such as the end of the deal to supply drugs between Roche and the state-funded hospitals in Greece, and the adoption by the European Commission (EC) of the revised proposals on supplying prescription-only drugs to the public.

  • It's Roche vs Schering-Plough for hepatitis-C market.  // Medical Marketing & Media;Nov2002, Vol. 37 Issue 11, p10 

    Reports on Roche AG's receipt of U.S. Food and Drug Administration approval for Pegasys, a drug for treatment of hepatitis C. Marketing program; Competition with PEG-Intron from Schering-Plough.

  • Roche's Pharma Pipeline Beginning to Blossom. Jarvis, Lisa // Chemical Market Reporter;9/3/2001, Vol. 260 Issue 9, p12 

    Presents information on potentially important products from Roche's pharmaceutical division as a result of improvements made in the research and development approach. Overview on Roche's hepatitis C treatment Pegasys; Company's cycle cell inhibitor for the treatment of solid tumors; Roche's...

  • Healthy combo.  // Business News New Jersey;10/02/96, Vol. 9 Issue 20, p3 

    Focuses on the business partnership formed between Bayer AG's Consumer Care Division and Roche Holding AG to market a batch of the firms' over-the-counter drugs.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics